Announcements Trials
Browse Landscape

Status

Completed 3

Sponsor Class

OTHER 9INDUSTRY 3

Study Type

Observational 3Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Other hematologic neoplasm 1Myeloid 1Genitourinary 1

Conditions

Neoplasms 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Carcinoma, Renal Cell 1

Interventions

Blood Specimen Collection 31Sorafenib 29Nivolumab 29Bevacizumab 26Data Collection 24Observation 23palbociclib 22Sunitinib 22radium Ra 223 dichloride 20enzalutamide 18Rituximab 18Ipilimumab 16regorafenib 15Drug Therapy 15Trastuzumab 14Docetaxel 14ribociclib 12exemestane 12atezolizumab 12Standard of Care 12darolutamide 11apalutamide 11Leuprolide 11Capecitabine 11Afatinib 11Bortezomib 10Anastrozole 10trastuzumab deruxtecan 9pembrolizumab 9avelumab 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Observational × Tyrosine Kinase Inhibitors × Clear all
NCT04375150 2024-09-19

Master Protocol to Study Treatment Patterns, Medication Adherence, Health and Economic Outcomes and Unmet Needs in RCC

Pfizer

Completed
355 enrolled 23 charts
Genitourinary

Carcinoma, Renal Cell

NCT05476562 2022-11-08

Study Conducted Among Patients With CML

Novartis

Completed
3,234 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01098500 2017-05-30

Liver Function Test (LFT) Elevations in Cancer Patients and Users of Tyrosine Kinase Inhibitor (TKI) Drugs

GlaxoSmithKline

Completed
3,800 enrolled 19 charts
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡